Watch ORIC. Know when insiders buy.
One email the day a filing lands. Free.
Work order
61
WATCH · insiders 26, shorts 96
Insiders, 90 days
−$1.1M
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.3BP/E —DIV YIELD —FCF YIELD -8.42%REV TTM —NET INCOME −$140.4MNET CASH $27M52W 7.47 – 14.65NEXT EARNINGS Nov 12 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$45.3M | −$41.5M | — | -0.38 | −$31.6M | $356K | −$32M | Aug 3 |
| Q1 2026 · Mar 31 | — | — | — | −$39.6M | −$35.8M | — | -0.34 | −$32.4M | $2K | −$32.4M | May 4 |
| Q4 2025 · Dec 31derived | — | — | — | −$34.6M | −$30.5M | — | -0.27 | −$22.5M | $227K | −$22.7M | Feb 23 |
| Q3 2025 · Sep 30 | — | — | — | −$36.7M | −$32.6M | — | -0.33 | −$25.1M | $35K | −$25.1M | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$39.1M | −$36.4M | — | -0.47 | −$30.8M | $63K | −$30.9M | Aug 3 |
| Q1 2025 · Mar 31 | — | — | — | −$32.7M | −$30M | — | -0.42 | −$32.5M | $387K | −$32.9M | May 4 |
| Q4 2024 · Dec 31derived | — | — | — | −$39.6M | −$36.3M | — | -0.51 | −$28.1M | $219K | −$28.3M | Feb 23 |
| Q3 2024 · Sep 30 | — | — | — | −$38.3M | −$34.6M | — | -0.49 | −$28.8M | $418K | −$29.2M | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$36M | −$32M | — | -0.45 | −$25.6M | $333K | −$26M | Aug 12 |
| Q1 2024 · Mar 31 | — | — | — | −$29M | −$25M | — | -0.37 | −$30.2M | $218K | −$30.4M | May 5 |
| Q4 2023 · Dec 31derived | — | — | — | −$31.4M | −$28.3M | — | -0.50 | −$24.3M | $57K | −$24.3M | Feb 18 |
| Q3 2023 · Sep 30 | — | — | — | −$28.7M | −$25.5M | — | -0.44 | −$19.6M | $77K | −$19.7M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$143M | −$129.5M | — | -1.47 | −$111M | $712K | −$111.7M | — | — |
| FY2024 · to Dec 31 | — | — | −$142.9M | −$127.8M | — | -1.83 | −$112.7M | $1.2M | −$113.8M | — | — |
| FY2023 · to Dec 31 | — | — | −$110.8M | −$100.7M | — | -1.96 | −$85.7M | $849K | −$86.5M | — | — |
| FY2022 · to Dec 31 | — | — | −$91.8M | −$89.1M | — | -2.25 | −$75.1M | $2.1M | −$77.2M | — | — |
| FY2021 · to Dec 31 | — | — | −$78.9M | −$78.7M | — | -2.07 | −$59.5M | $939K | −$60.5M | — | — |
| FY2020 · to Dec 31 | — | — | −$74.2M | −$73.7M | — | -3.36 | −$45.3M | $667K | −$45.9M | — | — |
Every number comes from Oric Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.